Fundraising Fox

GeneCentric

Durham, US · Founded 2011 · 14 employees on LinkedIn · 2 known investors

GeneCentric develops ExpressCT, a fragmentomics technology that extracts gene expression measurements from circulating tumor DNA sequencing data to enable expression-based biomarkers for cancer diagnostics and precision oncology. The company serves biopharma, diagnostics companies, and commercial laboratories.

BiotechDigital HealthMedical Devices

Founders & leadership

MM
MICHAEL MILBURNExecutive
CP
CHARLES PEROUNamed on SEC filing
DN
David Neil HayesNamed on SEC filing
CP
Charles PerouNamed on SEC filing
AL
Arnold LevineNamed on SEC filing

Board

CTCLAY THORP
CLAY THORPinBoard directorGeneral Partner at Hatteras Venture Partners
MLMyla Lai-Goldman
Myla Lai-GoldmaninCo-Founder and ChairVenture Partner at Hatteras Venture Partners
CT
Clay ThorpBoard director
AL
ARNOLD LEVINEBoard director
PR
Prasanth ReddyBoard director
DH
Don HardisonBoard director

Investors · 2

Hatteras Venture PartnersResearch Triangle · $500K – $4M
IAG Capital PartnersreportedCharleston

Reported raises · per SEC filings

Form D private placements

$21.3M disclosed across 6 rounds · 2013–2025

▶$2MraisedJun 2025 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CLAY THORPDirector
  • MICHAEL MILBURNExecutive Officer, Director
  • ARNOLD LEVINEDirector
  • CHARLES PEROUDirector
  • Prasanth ReddyDirector
  • MYLA LAI-GOLDMANDirector
  • Don HardisonDirector
Offering amount
$5M
Amount sold
$2M
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedSep 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • ARNOLD LEVINEDirector
  • CLAY THORPDirector
  • CHARLES PEROUDirector
  • MYLA LAI-GOLDMANDirector
  • ELLEN LUBMANDirector
  • MICHAEL MILBURNExecutive Officer, Director
Offering amount
$3.5M
Amount sold
$2.5M
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ellen LubmanDirector
  • Michael V. MilburnExecutive Officer, Director
  • Perou CharlesExecutive Officer, Director
  • Clay ThorpDirector
  • Myla Lai-GoldmanExecutive Officer, Director
  • Arnold LevineDirector
Offering amount
$7.5M
Amount sold
$4.5M
First sale
Sep 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedJan 2021 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles PerouExecutive Officer, Director
  • Arnold LevineDirector
  • Clay ThorpDirector
  • Michael MilburnExecutive Officer, Director
  • Myla Lai-GoldmanExecutive Officer, Director
  • Ellen LubmanDirector
Offering amount
$1.2M
Amount sold
$1.2M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedJan 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Myla Lai-GoldmanExecutive Officer, Director
  • Clay ThorpDirector
  • Arnold LevineDirector
  • David Neil HayesExecutive Officer, Director
  • Charles PerouDirector
Offering amount
$8.6M
Amount sold
$6.1M
First sale
Dec 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJul 2014 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles PerouDirector
  • Myla Lai-GoldmanExecutive Officer, Director
  • Arnold LevineDirector
  • David Neil HayesExecutive Officer, Director
  • Clay ThorpDirector
Offering amount
$5M
Amount sold
$5M
First sale
Jun 2013
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Labcorp8 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.

Companies competing with GeneCentric for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

GeneCentric secures $8m to launch liquid biopsy platformfinance.yahoo.com · Jun 2025GeneCentric Secures $8M Series C to Commercialize RNA-Based Liquid Biopsy Platformtrial.medpath.com · Jun 2025GeneCentric Announces Series C Financing to Advance Novel Liquid Biopsy Platform for Precision Oncologyfinance.yahoo.com · Jun 2025GeneCentric Therapeutics Holds Initial Closing of $8.0M Series C Financingfinsmes.com · Jun 2025Genomics startup GeneCentric in Durham raises $7.5M for commercialization effort | WRAL TechWirewraltechwire.com · Nov 2021Cancer tests: GeneCentric Diagnostics lands $250K in fundingmedcitynews.com · Sep 2011

Frequently asked questions

What does GeneCentric do?
GeneCentric develops ExpressCT, a fragmentomics technology that extracts gene expression measurements from circulating tumor DNA sequencing data to enable expression-based biomarkers for cancer diagnostics and precision oncology. The company serves biopharma, diagnostics companies, and commercial laboratories.
Who are GeneCentric's investors?
GeneCentric's investors include Hatteras Venture Partners, IAG Capital Partners.
How much funding has GeneCentric raised?
GeneCentric has disclosed $21.3M raised across 6 rounds.
Where is GeneCentric headquartered?
GeneCentric is headquartered in Durham, US.